Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis
Lung cancer remains the leading cause of cancer deaths worldwide[1]. Non-small cell lung cancer (NSCLC) represents 80-90% of lung primary malignancies. NSCLC is most often diagnosed at a metastatic stage, where 5-year survival rate ranges between 0 and 5% using traditional chemotherapy-based strategies[2]. The recent introduction of immune checkpoint inhibitors (ICI), has resulted in an increase in overall survival (OS) rates of patients with advanced NSCLC, as well as melanoma, urothelial carcinoma, renal cell carcinoma and head and neck carcinoma.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Urania Dafni, Zoi Tsourti, Katerina Vervita, Solange Peters Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Head and Neck Cancer | Kidney Cancer | Lung Cancer | Melanoma | Non-Small Cell Lung Cancer | Renal Cell Carcinoma | Skin Cancer